Pandemics & Epidemics

Johnson & Johnson is actively engaged in responding to and preventing a broad range of pandemic and epidemic threats; our experience in these areas has been built over more than a century. Our track record in advancing vaccines and novel treatment regimens and facilitating access to address multiple diseases such as HIV HIV Human immunodeficiency virus , TB TB Tuberculosis , COVID-19, Ebola, dengue and others, as well as addressing the growing threat of AMR AMR Antimicrobial resistance , has made a significant contribution to global public health and UN SDG SDG Sustainable Development Goal (of the United Nations) 3, which aspires to ensure healthy lives and promote well-being for all ages.

We maintain a wide range of collaborative partnerships to advance global health security and pandemic preparedness. One such collaboration, BLUE KNIGHT, is between JLABS JLABS Johnson & Johnson Innovation—JLABS and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, with the goal of accelerating the research and development of potential solutions for a range of diseases with pandemic potential. In 2021, the collaboration expanded residency opportunities to all JLABS and affiliate locations in North America as well as maintaining a virtual, global engagement model. By the end of 2021, the BLUE KNIGHT portfolio had grown to 19 companies globally, dedicated to anticipating potential health security threats, activating the global innovation community, and amplifying scientific and technological advancements.